Abstract:The ubiquitin-proteasome system (UPS) promotes the timely degradation of short-lived proteins with key regulatory roles in a vast array of biological processes, such as cell cycle progression, oncogenesis and genome integrity. Thus, abnormal regulation of UPS disrupts the protein homeostasis and causes many human diseases, particularly cancer. Indeed, the FDA approval of bortezomib, the first class of general proteasome inhibitor, for the treatment of multiple myeloma, demonstrated that the UPS can be an attractive anti-cancer target. However, normal cell toxicity associated with bortezomib, resulting from global inhibition of protein degradation, promotes the focus of drug discovery efforts on targeting enzymes upstream of the proteasome for better specificity. E3 ubiquitin ligases, particularly those known to be activated in human cancer, become an attractive choice. Cullin-RING Ligases (CRLs) with multiple components are the largest family of E3 ubiquitin ligases and are responsible for ubiquitination of similar to 20% of cellular proteins degraded through UPS. Activity of CRLs is dynamically regulated and requires the RING component and cullin neddylation. In this review, we will introduce the UPS and CRL E3s and discuss the biological processes regulated by each of eight CRLs through substrate degradation. We will further discuss how cullin neddylation controls CRL activity, and how CRLs are being validated as the attractive cancer targets by abrogating the RING component through genetic means and by inhibiting cullin neddylation via MLN4924, a small molecule indirect inhibitor of CRLs, currently in several Phase I clinical trials. Finally, we will discuss current efforts and future perspectives on the development of additional inhibitors of CRLs by targeting E2 and/or E3 of cullin neddylation and CRL-mediated ubiquitination as potential anti-cancer agents.

CRL3s: The BTB-CUL3-RING E3 Ubiquitin Ligases

The Functions and Properties of Cullin-5, a Potential Therapeutic Target for Cancers.

Cullin-RING ligases in regulation of autophagy

Cullin-RING E3 Ubiquitin Ligases: Bridges to Destruction.

Functional analysis of Cullin 3 E3 ligases in tumorigenesis

Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs

Pathogenic Roles of the Cullin E3 Ligase Scaffolding Protein CUL4B

A Conserved N-terminal Motif of CUL3 Contributes to Assembly and E3 Ligase Activity of CRL3KLHL22

The Characteristics and Roles of Β‐trcp1/2 in Carcinogenesis

A conserved N-terminal motif of CUL3 contributes to assembly and E3 ligase activity of CRL3 KLHL22

The functional analysis of Cullin 7 E3 ubiquitin ligases in cancer

Cullin-RING ligases employ geometrically optimized catalytic partners for substrate targeting

Noncanonical assembly, neddylation and chimeric cullin–RING/RBR ubiquitylation by the 1.8 MDa CUL9 E3 ligase complex

The emerging role for Cullin 4 family of E3 ligases in tumorigenesis

Cullin 4-DCAF Proteins in Tumorigenesis

Cullin–RING ubiquitin E3 ligase regulation by the COP9 signalosome

Targeting Cul3-scaffold E3 ligase complex <i>via</i> KLHL substrate adaptors for cancer therapy

Cryo-EM structure of the KLHL22 E3 ligase bound to an oligomeric metabolic enzyme

Modulation of Cullin-RING E3 ubiquitin ligase-dependent ubiquitination by small molecule compounds

Cullin-RING Ligases as attractive anti-cancer targets.

Crystal Structure of the Cul2-Rbx1-EloBC-VHL Ubiquitin Ligase Complex